Pfizer's PFE non-COVID operational revenues improved in 2024, driven by its key in-line products like Vyndaqel, Padcev and ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Stocks ended in the red for the holiday-shortened week, as developments over tariffs and tensions between U.S. President Donald Trump and Federal Reserve chair Jerome Powell continued to dominate ...

Victorian babies will be safer from Respiratory Syncytial Virus (RSV) this winter, with a long-acting immunisation available ...

The long-acting Respiratory Syncytial Virus (RSV) immunisation is now available free for eligible families until September 30 ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...